Malaria Clinical Trial
— LOPRIMOfficial title:
A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of Low Dose Primaquine for Clearance of Gametocytes in Asymptomatic Individuals Infected With P. Falciparum in Burkina Faso
Primaquine (PQ) is currently the only available drug that can clear mature transmission
stages of P. falciparum parasites. PQ was previously shown to clear gametocytes that persist
after artemisinin-combination therapy. However, there are safety concerns about the use of
PQ at the currently recommended dose of 0.75mg/kg in individuals who are glucose-6-phosphate
dehydrogenase (G6PD) deficient. PQ causes transient but significant haemolysis in G6PD
deficient individuals; this side-effect is dose dependent. There are indications that a
lower dosing of PQ may effectively reduce gametocyte carriage but the lowest efficacious
dose for gametocyte clearance is currently unknown. Recently, the World Health Organization
changed their recommendation to a low dose of primaquine, 0.25mg/kg. However, there is no
direct evidence on the extent to which (low dose) PQ prevents malaria transmission to
mosquitoes and what the lowest efficacious dose is.
In the current study we aim to identify the lowest efficacious dose of PQ in individuals
with normal G6PD function. Children with asymptomatic malaria and normal G6PD enzyme
function will be randomized to treatment with artemether-lumefantrine alone or in
combination with low doses of PQ. All enrolled individuals will receive a full three-day
course of AL, and will be randomized to receive a dose of primaquine or placebo with their
fifth dose of AL. Efficacy will be determined based on gametocyte carriage during follow-up,
measured by molecular methods. For a subset of participants with patent gametocytes,
primaquine effect on infectivity to mosquitoes will be assessed by membrane feeding assays
Status | Completed |
Enrollment | 360 |
Est. completion date | July 2015 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 2 Years to 15 Years |
Eligibility |
Inclusion Criteria: 1. Age > 2 years and <15 years 2. Weight over 10kg 3. P. falciparum parasitaemia >1,000 parasites and <200,000 parasites/µl 4. P. falciparum gametocytes detected by microscopy 5. Normal G6PD enzyme function 6. Informed consent by legally acceptable representative Exclusion Criteria: 1. Enrolled in another study 2. Fever or history of fever in the last 24 hours 3. Evidence of severe illness/ danger signs 4. Known allergy to study medications 5. Hb < 8g/dL 6. Started menstruation 7. Pregnancy or breastfeeding 8. Antimalarials taken within the last 2 days 9. Primaquine taken within the last 4 weeks 10. Blood transfusion within the last 90 days 11. Non-falciparum malaria co-infection |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Burkina Faso | Centre National de Recherche et de Formation sur le Paludisme | Ouagadougou |
Lead Sponsor | Collaborator |
---|---|
London School of Hygiene and Tropical Medicine | Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso, Radboud University |
Burkina Faso,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gametocyte carriage | Gametocyte prevalence at enrolment and on days 2, 3, 7, 10, 14 during follow-up. The duration of gametocyte carriage in days will be estimated. |
14 days during follow-up | No |
Secondary | Transmission to Anopheles gambiae mosquitoes | Mosquito membrane feeding assays will be used to determine the proportion of infected mosquitoes and the oocyst burden in infected mosquitoes. | day -1, day 3, day 7 | No |
Secondary | Haematological recovery | Haemoglobin concentration will be determined at enrolment and on days 2, 3, 7, 10 and 14 during follow-up. Haemoglobin concentration will be presented as grams per decilitre and as concentration relative to enrolment value. | 14 days during follow-up | Yes |
Secondary | Primaquine and lumefantrine pharmacokinetics | The pharmacokinetic sampling will measure primaquine, lumefantrine and metabolites. Sampling involves 7 venous blood samples during the first 72 hours after treatment and a single later time point at day 7 post initiation of treatment. Drug plasma levels will be related to treatment arm and to the participant's Cytochrome P450 2D6 metabolizer status. CYP2D6 is an enzyme involved in primaquine metabolism. | 7 days during follow-up | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02527005 -
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
|
Phase 1 |